Niinivirta, A., Salo, T., Åström, P., Juurikka, K., & Risteli, M. (2022). Prognostic value of dysadherin in cancer: A systematic review and meta-analysis. Frontiers in Oncology, 12, 945992. https://doi.org/10.3389/fonc.2022.945992
Prognostic value of dysadherin in cancer : a systematic review and meta-analysis
|Author:||Niinivirta, Aino1,2; Salo, Tuula1,2,3,4,5; Åström, Pirjo6;|
1Cancer and Translational Medicine Research Unit, Faculty of Medicine, University of Oulu, Oulu, Finland
2Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland
3Department of Oral and Maxillofacial Diseases, University of Helsinki, and Helsinki University Central Hospital, Helsinki, Finland
4Department of Pathology (HUSLAB), Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland
5Translational Immunology Research Program (TRIMM), University of Helsinki, Helsinki, Finland
6Research Unit of Biomedicine, Faculty of Medicine, University of Oulu, Oulu, Finland
|Online Access:||PDF Full Text (PDF, 1.7 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe202301276275
|Publish Date:|| 2023-01-27
Cancer is a leading cause of death worldwide and novel prognostic factors are reported with increasing numbers. Systematic reviews and meta-analyses on cumulative research data are crucial in estimating the true prognostic value of proposed factors. Dysadherin (FXYD Domain Containing Ion Transport Regulator 5; FXYD5) is a cell membrane glycoprotein that modulates Na+, K+-ATPase activity and cell-cell adhesion. It is abundantly expressed in a variety of cancer cells, but only in a limited number of normal cells and its levels are increased in many different tumor types. The expression or level of dysadherin has been suggested as an independent predictor for metastasis and poor prognosis by number of studies, yet we lack a definitive answer. In this study, we systematically evaluated the prognostic value of dysadherin in cancer and summarized the current knowledge on the subject. PubMed, Scopus, Web of Science and relevant clinical trial and preprint databases were searched for relevant publications and PRISMA and REMARK guidelines were applied in the process. After a careful review, a total of 23 original research articles were included. In each study, dysadherin was pointed as a marker for poor prognosis. Meta-analyses revealed 3- and 1.5-fold increases in the risk of death (fixed effects HR 3.08, 95% CI 1.88–5.06, RR 1.47, 95% CI 1.06–2.05 on overall survival, respectively) for patients with high (>50%) tumoral FXYD5 level. In many studies, a connection between dysadherin expression or level and metastatic behavior of the cancer as well as inverse correlation with E-cadherin level were reported. Thus, we conclude that dysadherin might be a useful prognostic biomarker in the assessment of disease survival of patients with solid tumors.
Frontiers in oncology
|Type of Publication:||
A2 Review article in a scientific journal
|Field of Science:||
This study received funding from the Medical Faculty of the University of Oulu and Oulu University Hospital special state support for research. PÅ received funding from the Academy of Finland (#308363).
|Academy of Finland Grant Number:||
308363 (Academy of Finland Funding decision)
© 2022 Niinivirta, Salo, Åström, Juurikka and Risteli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.